{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:18:46Z","timestamp":1782245926137,"version":"3.54.5"},"reference-count":40,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,3]]},"abstract":"<jats:p>\n                    Leishmaniasis is a complex tropical disease caused by kinetoplastid parasitic protozoa of the genus\n                    <jats:italic>Leishmania<\/jats:italic>\n                    and is transmitted by the sand fly insect vector. Cutaneous leishmaniasis (CL) is the most common form of this disease, and CL infections often result in serious skin lesions and scars. CL remains a public health problem in many endemic countries worldwide because of the absence of effective, safe, and cost-effective drugs for treatment. One of the strategies we chose to use to find novel chemical entities worthy of further development as antileishmanials involved screening synthetic and natural products libraries. In our study, we developed a\n                    <jats:italic>Leishmania major<\/jats:italic>\n                    intracellular amastigote assay that uses the activity of luciferase as a measure of parasite proliferation and used this assay to screen a collection of 400 compounds obtained from Medicines for Malaria Venture (MMV) for their antileishmanial activity. Our results showed that 14 compounds identified by MMV as antimalarial drugs have antileishmanial activity and can potentially be optimized for CL drug development.\n                  <\/jats:p>","DOI":"10.4269\/ajtmh.15-0448","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T21:53:37Z","timestamp":1445896417000},"page":"340-347","source":"Crossref","is-referenced-by-count":31,"title":["Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major Amastigotes"],"prefix":"10.4269","volume":"94","author":[{"given":"Mozna","family":"Khraiwesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Leed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Roncal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Grogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"ref1","series-title":"World Health Organ Tech Rep Ser","first-page":"1","article-title":"Control of the leishmaniases","volume":"949","author":"World Health Organization","year":"2010"},{"key":"ref2","series-title":"Trends Parasitol","first-page":"502","article-title":"Leishmaniasis\u2014current chemotherapy and recent advances in the search for novel drugs","volume":"19","author":"Croft","year":"2003"},{"key":"ref3","series-title":"Clin Dermatol","first-page":"425","article-title":"Cutaneous leishmaniasis: clinical aspect","volume":"14","author":"Dowlati","year":"1996"},{"key":"ref4","series-title":"Am J Trop Med Hyg","first-page":"216","article-title":"Review: drug discovery algorithm for cutaneous leishmaniasis","volume":"88","author":"Grogl","year":"2013"},{"key":"ref5","series-title":"FEMS Immunol Med Microbiol","first-page":"27","article-title":"Deciphering the Leishmania exoproteome: what we know and what we can learn","volume":"58","author":"Corrales","year":"2010"},{"key":"ref6","series-title":"Eur J Pharmacol","first-page":"90","article-title":"Rational drug design","volume":"625","author":"Mandal","year":"2009"},{"key":"ref7","series-title":"Curr Org Chem","first-page":"643","article-title":"Natural products for neglected diseases: a review","volume":"12","author":"Ioset","year":"2008"},{"key":"ref8","series-title":"J Med Chem","first-page":"7719","article-title":"Drug discovery for neglected diseases: molecular target-based and phenotypic approaches","volume":"56","author":"Gilbert","year":"2013"},{"key":"ref9","series-title":"Nature","first-page":"305","article-title":"Thousands of chemical starting points for antimalarial lead identification","volume":"465","author":"Gamo","year":"2010"},{"key":"ref10","series-title":"Nature","first-page":"311","article-title":"Chemical genetics of Plasmodium falciparum","volume":"465","author":"Guiguemde","year":"2010"},{"key":"ref11","series-title":"Science","first-page":"1372","article-title":"Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery","volume":"334","author":"Meister","year":"2011"},{"key":"ref12","series-title":"PLoS One","first-page":"e62906","article-title":"The open access malaria box: a drug discovery catalyst for neglected diseases","volume":"8","author":"Spangenberg","year":"2013"},{"key":"ref13","series-title":"J Biomol Screen","first-page":"634","article-title":"Repurposing of the open access malaria box for kinetoplastid diseases identifies novel active scaffolds against trypanosomatids","volume":"20","author":"Kaiser","year":"2015"},{"key":"ref14","series-title":"Am J Trop Med Hyg","first-page":"600","article-title":"Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages","volume":"72","author":"Buckner","year":"2005"},{"key":"ref15","series-title":"Kinetoplastid Biol Dis","first-page":"6","article-title":"Leishmania amastigotes as targets for drug screening","volume":"5","author":"Monte-Alegre","year":"2006"},{"key":"ref16","series-title":"PLoS Negl Trop Dis","first-page":"e1253","article-title":"A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit","volume":"5","author":"De Muylder","year":"2011"},{"key":"ref17","series-title":"Antimicrob Agents Chemother","first-page":"2913","article-title":"Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay","volume":"57","author":"De Rycker","year":"2013"},{"key":"ref18","series-title":"PLoS Negl Trop Dis","first-page":"e1671","article-title":"An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages","volume":"6","author":"Siqueira-Neto","year":"2012"},{"key":"ref19","series-title":"Parasitol Today","first-page":"143","article-title":"Axenic culture of Leishmania amastigotes","volume":"9","author":"Bates","year":"1993"},{"key":"ref20","series-title":"Antimicrob Agents Chemother","first-page":"818","article-title":"An axenic amastigote system for drug screening","volume":"41","author":"Callahan","year":"1997"},{"key":"ref21","series-title":"Parasitol Res","first-page":"963","article-title":"A simple and reproducible method to obtain large numbers of axenic amastigotes of different Leishmania species","volume":"88","author":"Teixeira","year":"2002"},{"key":"ref22","series-title":"Mol Biochem Parasitol","first-page":"198","article-title":"Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana","volume":"146","author":"Holzer","year":"2006"},{"key":"ref23","series-title":"Parasitol Res","first-page":"821","article-title":"Comparison of the expression profiles of promastigotes and axenic amastigotes in Leishmania donovani using serial analysis of gene expression","volume":"103","author":"Li","year":"2008"},{"key":"ref24","series-title":"Antimicrob Agents Chemother","first-page":"3855","article-title":"In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences","volume":"53","author":"Vermeersch","year":"2009"},{"key":"ref25","series-title":"Cell Microbiol","first-page":"383","article-title":"Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice","volume":"7","author":"Lang","year":"2005"},{"key":"ref26","series-title":"Indian J Exp Biol","first-page":"475","article-title":"High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay","volume":"47","author":"Mandal","year":"2009"},{"key":"ref27","series-title":"PLoS Negl Trop Dis","first-page":"e34","article-title":"Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL\/6 model","volume":"1","author":"Lecoeur","year":"2007"},{"key":"ref28","series-title":"J Biomol Screen","first-page":"67","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999"},{"key":"ref29","series-title":"J Immunol Methods","first-page":"165","article-title":"MTT colorimetric assay for testing macrophage cytotoxic activity in vitro","volume":"131","author":"Ferrari","year":"1990"},{"key":"ref30","series-title":"Cell-Based Assays for High-Throughput Screening","author":"Clemons","year":"2009"},{"issue":"Suppl 1","key":"ref31","series-title":"Trans R Soc Trop Med Hyg","first-page":"S127","article-title":"Drug sensitivity of Leishmania species: some unresolved problems","volume":"96","author":"Croft","year":"2002"},{"key":"ref32","series-title":"Acta Trop","first-page":"151","article-title":"Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B","volume":"81","author":"Escobar","year":"2002"},{"key":"ref33","series-title":"J Pharm Pharmacol","first-page":"1043","article-title":"In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis","volume":"58","author":"Garnier","year":"2006"},{"key":"ref34","series-title":"Antimicrob Agents Chemother","first-page":"1898","article-title":"In vitro life cycle of pentamidine-resistant amastigotes: stability of the chemoresistant phenotypes is dependent on the level of resistance induced","volume":"41","author":"Sereno","year":"1997"},{"key":"ref35","series-title":"Antimicrob Agents Chemother","first-page":"752","article-title":"Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis","volume":"41","author":"Yardley","year":"1997"},{"key":"ref36","article-title":"Properties were calculated using SARvision software (Version 3.3)"},{"key":"ref37","article-title":"8-hydroxyquinoline compounds and methods thereof","author":"Bursavich","year":"2008"},{"key":"ref38","series-title":"Oncogene","first-page":"213","article-title":"Modulation of Wnt\/\u03b2-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer","volume":"31","author":"Coombs","year":"2012"},{"key":"ref39","article-title":"Methods of treatment using wnt inhibitors","author":"Virshup","year":"2010"},{"key":"ref40","series-title":"Anal Chem","first-page":"1557","article-title":"Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method","volume":"81","author":"Spooner","year":"2009"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/94\/2\/article-p340.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/94\/2\/article-p340.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/94\/2\/article-p340.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T18:14:18Z","timestamp":1723054458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/94\/2\/article-p340.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,3]]},"references-count":40,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.15-0448","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725883243.793523087","asserted-by":"object"}]},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,3]]}}}